Business Update Neutral

2026-05-30 12:21

Natco Pharma Limited submitted the transcript of its earnings conference call for Q4 FY25-26, which was held on May 29, 2026. The transcript is enclosed and also available on the company's website.

Financials Negative

2026-05-29 15:32

Consolidated Revenue ₹8,169 Mn vs ₹12,873 Mn (▼36.5% YoY), EBITDA ₹2,054 Mn vs ₹6,144 Mn (▼66.6% YoY), PAT ₹2,690 Mn vs ₹4,060 Mn (▼33.7% YoY). EBITDA Margin 25.1% vs 47.7% (▼2260bps).

Financials Negative

2026-05-29 14:22

NATCO Pharma Limited reported consolidated Q4 FY26 results with Total Income of ₹816.9 Cr compared to ₹1,287.3 Cr in Q4 FY25 (▼36.6% YoY). EBITDA was ₹127.6 Cr vs ₹548.1 Cr (▼76.7% YoY). Net Profit (PAT) stood at ₹269.0 Cr vs ₹406.0 Cr (▼33.7% YoY). EBITDA Margin significantly contracted to 15.6% from 42.6% (▼2700bps). Q4 FY26 PAT includes a one-time deferred tax asset benefit of ₹115.0 Cr.

Business Update Neutral

2026-05-21 12:29

Natco Pharma Limited will host an earnings call for investors and analysts on Friday, May 29, 2026, at 4:30 PM IST. The call, hosted by 360 ONE Capital Market Private Limited, will discuss the company's Audited Financial Results for the quarter and year ended March 31, 2026. Key management, including the Vice-chairman and CEO, CFO, and EVP, Crop Health Sciences, will participate.

Business Update Negative

2026-05-14 16:19

CRITICAL RED FLAG DETECTED

Natco Pharma Limited received a demand notice on May 12, 2026, from the National Pharmaceutical Pricing Authority. The notice directs the company to deposit ₹4,92,25,923/-, including overcharge, penalty, and interest, for allegedly overcharging on two drugs between April 2023 and November 2023. The company stated there is no material impact on its financial, operational, or other activities.

Routine Neutral

2026-04-09 10:52

Natco Pharma Limited submitted the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026, confirming securities received for dematerialization were processed and depository records updated.

Routine Neutral

2026-03-31 13:58

Natco Pharma Ltd. announced the closure of the trading window for Directors, Designated Persons, and connected persons from April 1, 2026, until 48 hours after the declaration of financial results for the quarter and year ending March 31, 2026. The date of the Board Meeting will be intimated in due course.

Governance Positive

2026-03-25 15:44

Natco Pharma announced the results of its postal ballot held from February 12 to March 24, 2026. All resolutions were passed with requisite majority, confirming the re-appointment of Sri V. C. Nannapaneni as Chairman & MD, Sri Rajeev Nannapaneni as Vice Chairman & CEO, and two other directors with effect from April 1, 2026.

Governance Positive

2026-03-24 17:16

Natco Pharma's board approved demerging its Agrochemicals Business into Natco Crop Health Sciences Ltd, effective October 1, 2026. Shareholders get 1 share of the new entity for every 1 held. Also approved: forming a Nigerian subsidiary and liquidating an Australian one.

Business Update Positive

2026-03-20 09:32

Natco Pharma launched Semaglutide Generic Injection multi-dose vials in India on March 20, 2026, at an affordable price starting from INR 1,290 per month. It's the first to offer this GLP-1 therapy in vial form, making it significantly cheaper than innovator brands.

Business Update Neutral

2026-03-06 10:25

Natco Pharma Limited announced participation in the Investec Promoter and Founder Conference 2026 on March 9, 2026, in Mumbai. No Unpublished Price Sensitive Information will be discussed during the meeting.

Business Update Positive

2026-03-03 10:31

NATCO Pharma Limited announced on March 3, 2026, the launch of Pomalidomide Capsules (generic of Pomalyst®) in the U.S. market, in partnership with Breckenridge Pharmaceutical, Inc. The generic drug targets multiple myeloma and AIDS-related Kaposi sarcoma. Pomalidomide Capsules had estimated sales of USD 3.2 billion in the U.S. for 12 months ending Sep '25.

Business Update Positive

2026-02-25 10:02

Natco Pharma confirmed receiving CDSCO approval for Semaglutide in India on Feb 14, 2026. The company plans to launch the product with marketing partners, including Eris Lifesciences Ltd, in March 2026. They stated the partnership has no material financial impact.

Routine Neutral

2026-02-24 16:55

New Filing detected. See link for details.

Governance Neutral

2026-02-20 13:03

Natco Pharma announced a Postal Ballot to seek shareholder approval for the re-appointment of four directors, including Chairman & MD V.C. Nannapaneni and Vice Chairman & CEO Rajeev Nannapaneni, for a period of one year from April 1, 2026 to March 31, 2027. E-voting will take place from February 23 to March 24, 2026, with results declared by March 26, 2026.

Financials Positive

2026-02-18 15:36

Consolidated Revenue ₹705.4Cr vs ₹651.1Cr (▲8.3% YoY). For the quarter ended December 31, 2025, EBITDA was ₹216.8Cr and Net Profit was ₹151.3Cr. EBITDA Margin stood at 30.7%. An interim dividend of INR 1.5 per share was declared.

Business Update Positive

2026-02-14 09:32

NATCO Pharma Limited received approval from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. This product, for type 2 diabetes, is scheduled for launch in the Indian market by March 2026.

Business Update Positive

2026-02-13 09:19

Natco Pharma Limited's API unit in Chennai received an Establishment Inspection Report (EIR) from the U.S. FDA, classifying the inspection as Voluntary Action Indicated (VAI). The inspection, held November 17-21, 2025, had 7 Form 483 observations.

Business Update Neutral

2026-02-12 18:04

Natco Pharma Limited informed about the uploading of the audio recording of its Q3 FY25-26 earnings conference call, held on February 12, 2026, to the company's website. The recording is available for access by investors.

Financials Positive

2026-02-12 15:50

Natco Pharma Limited declared a 3rd interim dividend of Rs. 1.50/- (75%) per equity share for FY 2025-26. The record date for eligibility is Wednesday, February 18, 2026, with payment commencing from February 26, 2026.

Business Update Positive

2026-02-12 15:49

On February 12, 2026, Natco Pharma Limited's Board approved the incorporation of a wholly-owned subsidiary, NATCO Pharma Chile SPA, in Chile, with an investment not exceeding US$300,000, to engage in the pharmaceuticals business.

Governance Positive

2026-02-12 15:46

CRITICAL RED FLAG DETECTED

NATCO Pharma announced Mr. S.V.V.N. Appa Rao's superannuation as CFO on Feb 12, 2026. Mr. Amit Parekh was appointed as the new CFO from Feb 13, 2026. Additionally, Mr. Kalakuntla Srinivas Rao was appointed Executive Vice President – Pharma Division from Feb 12, 2026, strengthening the leadership team.

Governance Positive

2026-02-12 15:46

NATCO Pharma announced the superannuation of its CFO, Mr. S.V.V.N. Appa Rao, on Feb 12, 2026. Mr. Amit Parekh was appointed as the new CFO (effective Feb 13, 2026), and Mr. Kalakuntla Srinivas Rao as EVP – Pharma Division, bringing extensive industry experience.

Governance Neutral

2026-02-12 15:46

Natco Pharma announced CFO Mr. S.V.V.N. Appa Rao's superannuation on Feb 12, 2026. Mr. Amit Parekh is appointed as the new CFO from Feb 13, 2026. Mr. Kalakuntla Srinivas Rao also appointed EVP – Pharma Division from Feb 12, 2026.

Financials Positive

2026-02-12 15:03

Consolidated Revenue ₹7,054 Mn vs ₹6,511 Mn (▲8.34% YoY). Q3FY26 EBITDA ₹2,168 Mn, PAT ₹1,513 Mn. EBITDA Margin 30.7%.

Financials Positive

2026-02-12 14:41

Consolidated Revenue ₹647.3Cr vs ₹474.8Cr (▲36.3% YoY), EBITDA ₹158.7Cr vs ₹38.8Cr (▲309.0% YoY), PAT ₹151.5Cr vs ₹133.0Cr (▲13.9% YoY). EBITDA Margin 24.5% vs 8.2% (▲1630bps).

Financials Positive

2026-02-12 14:33

Consolidated Revenue ₹647.3Cr vs ₹474.8Cr (▲36.3% YoY), EBITDA ₹158.7Cr vs ₹38.8Cr (▲309.0% YoY), PAT ₹151.3Cr vs ₹132.4Cr (▲14.3% YoY). EBITDA Margin 24.5% vs 8.2% (▲1630bps). The company also declared an interim dividend of ₹1.50 per equity share and approved the incorporation of a new subsidiary in Chile.

NATCOPHARM

Natco Pharma Limited

Filing History

Unlock Full History